Recombinant factor XIII prophylaxis is safe and effective in young children with congenital FXIII ‐A deficiency: international phase 3b trial results

ConclusionsConsistent with data from older age groups, prophylaxis with rFXIII appears to be safe and effective in young children with congenital FXIII A‐subunit deficiency.This article is protected by copyright. All rights reserved.

Source: Journal of Thrombosis and Haemostasis - June 5, 2017 Category: Hematology Authors: Bryce A. Kerlin, Aida Inbal, Andrew Will, Michael Williams, May ‐Lill Garly, Lotte Jacobsen, Susan L. Kearney Tags: Brief Report ‐ Clinical Haemostasis and Thrombosis Source Type: research